SNGX SOLIGENIX, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 812796 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY-85.8%
TTM net income YoY-34.6%
TTM EPS YoY60.7%
Revenue 3-yr CAGR-47.5%
Net income 3-yr CAGR—
Margins
Gross margin0.0%
Operating margin-7,907.7%
Net margin-6,925.1%
FCF margin—
EBITDA margin—
Returns
ROE-249.0%
ROA-88.1%
ROIC (approx.)—
Asset turnover0.01x
Leverage & solvency
Liabilities / assets54.1%
Debt / equity0.00x
Current ratio1.82x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.02x
Accruals ratio1.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | $119,371 | $839,359 | $948,911 | $824,268 |
| Cost of revenue | — | $119,371 | $742,048 | $550,822 | $728,640 |
| Gross profit | — | $0 | $97,311 | $398,089 | $95,628 |
| R&D expense | $7.49M | $5.22M | $3.31M | $7.94M | $8.19M |
| SG&A expense | $4.36M | $4.22M | $4.48M | $6.69M | $5.01M |
| Operating income | -$11.85M | -$9.44M | -$7.70M | -$14.24M | -$13.10M |
| Pretax income | -$11.59M | -$8.68M | -$7.91M | -$14.95M | -$13.42M |
| Income tax | -$506,615 | -$409,114 | -$1.77M | -$1.15M | -$864,742 |
| Net income | -$11.08M | -$8.27M | -$6.14M | -$13.80M | -$12.55M |
| EBITDA | — | — | — | — | -$13.06M |
| EPS (basic) | -2.14 | -4.98 | -12.66 | -4.81 | -4.69 |
| EPS (diluted) | -2.14 | -4.98 | -12.66 | -4.81 | -4.69 |
| Weighted avg. shares (diluted) | 5.19M | 1.66M | 484,995 | 2.87M | 2.68M |
| Banking | |||||
| Net interest income | — | — | — | — | -$862,577 |
| Deposits | — | — | — | — | $250,000 |
| Balance sheet | |||||
| Cash & equivalents | $7.94M | $7.82M | $8.45M | $13.36M | $26.04M |
| Current assets | $8.85M | $8.83M | $9.51M | $13.85M | $26.57M |
| PP&E, net | $8,772 | $6,113 | $11,927 | $18,481 | $22,220 |
| Total assets | $9.24M | $8.97M | $9.80M | $14.28M | $26.87M |
| Current liabilities | $3.70M | $4.85M | $6.15M | $16.52M | $6.29M |
| Long-term debt | — | $0 | $1.01M | $0 | — |
| Total debt | — | $0 | $1.01M | $0 | — |
| Total liabilities | $3.94M | $4.85M | $7.27M | $16.75M | $16.15M |
| Shareholders' equity | $5.29M | $4.12M | $2.52M | -$2.47M | $10.72M |
| Net debt | — | -$7.82M | -$7.44M | -$13.36M | — |
| Shares outstanding | 10.09M | 2.51M | 648,761 | 2.91M | 2.86M |
| Cash flow statement | |||||
| Operating cash flow | -$10.27M | -$8.40M | -$8.60M | -$12.65M | -$11.74M |
| Capital expenditure | $5,883 | — | — | — | — |
| Free cash flow | -$10.27M | — | — | — | — |
| Investing cash flow | -$5,883 | — | — | -$13,073 | -$11,789 |
| Financing cash flow | $10.39M | $7.76M | $3.66M | $76,821 | $19.06M |
| Depreciation & amortization | — | — | — | — | $34,161 |
| Stock-based compensation | $587,583 | $329,815 | $370,182 | $333,389 | $361,559 |
Free plan shows the latest 5 periods; Pro shows all 16 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.